APS:CA:TSX-Aptose Biosciences Inc (CAD)

COMMON STOCK | Biotechnology | TSX

Last Closing Price

CAD 7.71

Change

0.00 (0.00)%

Market Cap

CAD 0.67B

Volume

0.02M

Average Target Price

CAD 12.00 (+55.64%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1b clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a bioavailable non-covalent small molecule that is in Phase 1a/b clinical trial for the treatment of patients with relapsed/refractory acute myeloid leukemia and various B-cell malignancies. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada. Address: 251 Consumers Road, Toronto, ON, Canada, M2J 4R3

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
AUP:CA Aurinia Pharmaceuticals Inc

N/A

CAD2.41B N/A N/A
TRIL:CA Trillium Therapeutics Inc

N/A

CAD1.79B 1.80 N/A
LMNL:CA Liminal BioSciences Inc

N/A

CAD0.54B 1.28 N/A
IMV:CA IMV Inc

N/A

CAD0.40B -99,999.99 N/A
RVX:CA Resverlogix Corp

N/A

CAD0.29B 1.74 2.36
MDNA:CA Medicenna Therapeutics Corp

N/A

CAD0.26B 5.40 N/A
FRX:CA Fennec Pharmaceuticals Inc

N/A

CAD0.20B 30.20 N/A
BLU:CA BELLUS Health Inc

N/A

CAD0.18B N/A N/A
ONC:CA Oncolytics Biotech Inc

N/A

CAD0.09B N/A N/A
HBP:CA Helix BioPharma Corp

N/A

CAD0.05B N/A N/A

ETFs Containing APS:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.90% 67% D+ 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.90% 67% D+ 72% C-
Trailing 12 Months  
Capital Gain 157.00% 67% D+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 157.00% 67% D+ 98% A+
Trailing 5 Years  
Capital Gain 32.93% 64% D 69% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.93% 64% D 63% D
Average Annual (5 Year Horizon)  
Capital Gain 56.18% N/A N/A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 56.18% N/A N/A 97% A+
Risk Return Profile  
Volatility (Standard Deviation) 115.54% N/A N/A 4% F
Risk Adjusted Return 48.62% N/A N/A 66% D
Market Capitalization 0.67B 88% B+ 71% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 6.17 64% D 12% F
Price / Cash Flow Ratio -31.29 88% B+ 93% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -74.05% 73% C 11% F
Return on Invested Capital -49.73% 63% D 6% F
Return on Assets -43.14% 50% F 3% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 15.53 6% F 5% F
Short Percent 0.49% 50% F 93% A
Beta 0.95 56% F 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.